Lilly Cialis Delay Clears Space For Bayer Nuviva: Extra FDA Caution Cited
Executive Summary
The delay in the FDA review of Lilly/Icos' Cialis creates an opening for Bayer to establish Nuviva as the primary challenger to Pfizer's Viagra in the oral erectile dysfunction class
You may also be interested in...
Cialis NDA Issues Include Back Pain At 20 Mg Dose, FDA Documents Show
FDA's safety questions about Lilly/Icos' erectile dysfunction agent Cialis focus on back pain reported at the starting dose initially proposed by the companies
Cialis NDA Issues Include Back Pain At 20 Mg Dose, FDA Documents Show
FDA's safety questions about Lilly/Icos' erectile dysfunction agent Cialis focus on back pain reported at the starting dose initially proposed by the companies
Lilly/ICOS Cialis
Lilly/ICOS erectile dysfunction treatment Cialis (tadalafil) action date will fall in the fourth quarter of 2003. The companies submitted a complete response in the second quarter to an "approvable" letter (1"The Pink Sheet" May 6, 2002, p. 26). The joint venture expects a six-month review of the response, which includes pharmacology studies...